Clinical epidemiology and treatment of lichen planus: A retrospective review of 2 tertiary care centers

Schwager, Zachary; Stern, Marleigh J.; Cohen, Jeffrey M.; Femia, Alisa

doi:10.1016/j.jaad.2019.04.027

Cited by 24 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The frequency of metabolic syndrome was significantly lower, especially in the patient group with mild severity. This situation is thought to be due to the effect of cytokines increasing due to the increase of disease severity in lichen planus as in psoriasis 23 . The fact that the severity of oral disease and MS is unrelated suggests that the effect of oral disease burden on the whole body is less due to being a limited area.…”

Section: Discussionmentioning

confidence: 99%

The relationship between lichen planus and metabolic syndrome

Daye

Temiz

Işık

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Objective Lichen planus (LP) is an idiopathic, chronic inflammatory disease. Chronic inflammatory diseases can cause metabolic complications. In the literature, data related to the relationship between lichen planus and metabolic syndrome (MS) are limited. We aimed to evaluate the relationship between MS and lichen planus with disease activity. Methods The patients diagnosed with lichen planus at the dermatology outpatient clinic between January 2018 and January 2020 were retrospectively analyzed. 98 lichen planus cases, age‐ and sex‐matched 99 controls, 197 cases in total were included in the study. Results Of the 98 lichen planus cases included in the study, 60 (61%) were women. The mean age of the patients was 49.3 ± 14.4, and the average disease duration was 33.5 ± 31.4 months. 55 (55%) of the patients in the control group were female, and the mean age of the control group was 50 ± 13.2. The body mass index of LP cases was 29.5 ± 5.8, in the control group was 25.8 ± 3.7. Metabolic syndrome was found in 47 (48%) of 98 cases with lichen planus and 32.3% in the control group. MS in the lichen planus group was significantly higher than the control group (P = .025). Metabolic syndrome was detected in the oral lichen planus at the rate of 60% (12 cases). Although the incidence of MS was more common in the oral lichen planus, it was not statistically significant (P = .29). While no significant relationship was found between oral disease severity and metabolic syndrome (P = .19), a significant correlation was found between cutaneous disease severity and metabolic syndrome (P = .023). Discussion The risk of mucosal malignancy that can occur when following LP cases has been known for a long time. According to our results, caution should be taken in terms of metabolic complications in the follow‐up of LP cases, especially oral LP cases.

show abstract

Section: Discussionmentioning

confidence: 99%

The relationship between lichen planus and metabolic syndrome

Daye

Temiz

Işık

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…While oral LP affects females more frequently than males ( 24 , 30 ), cutaneous LP does not demonstrate a prominent sex predilection ( 21 ). Cutaneous LP tends to manifest during the fifth and sixth decades of life, with almost two-thirds of patients presenting with the disease between the ages of 30 and 60 years ( 9 , 31 , 32 ). Oral LP tends to develop 10 years later than cutaneous LP ( 33 ).…”

Section: Epidemiologymentioning

confidence: 99%

Lichen Planus

et al. 2021

View full text Add to dashboard Cite

Lichen planus (LP) is a T cell-mediated disease affecting the stratified squamous epithelia of the skin and/or mucus membrane. Histologically, the disease is characterized by a lichenoid inflammatory infiltrate and vacuolar degeneration of the basal layer of the epidermis. LP has three major subtypes: Cutaneous, mucosal and appendageal LP. Rarely, it may affect the nails in the absence of skin and/or mucosal changes. LP may also be induced by several drugs, typically anti-hypertensive medication or be associated with infections, particularly viral hepatitis. The diagnosis is based on the clinical presentation and characteristic histological findings. Although the disease is often self-limiting, the intractable pruritus and painful mucosal erosions result in significant morbidity. The current first-line treatment are topical and/or systemic corticosteroids. In addition, immunosuppressants may be used as corticosteroid-sparing agents. These, however are often not sufficient to control disease. Janus kinase inhibitors and biologics (anti-IL-12/23, anti-IL17) have emerged as novel future treatment options. Thus, one may expect a dramatic change of the treatment landscape of LP in the near future.

show abstract

“…Erosive lichen planus (ELP) is a severe variant, leading to ulcers and possibly cancerous transformation of mucous membranes [1]. There are no standardized treatments, and the success of off-label therapies including steroids, retinoids and methotrexate can vary greatly [2,3]. We report on the first patient with severe oral and esophageal ELP to be successfully treated with the JAK inhibitor upadacitinib.…”

mentioning

confidence: 99%